Patients in different CKD stages did not display considerable differences in terms of medication (antihypertensive agents, glucose lowering, immune suppressants), except for increased use of erythropoietin in CKD5D and CKD5D ASA, and lipid-lowering medication in CKD5D ASA. The gene discussed is EPO; the disease is chronic kidney disease.